Omalizumab and the immune system: an overview of preclinical and clinical data
- 1 August 2002
- journal article
- review article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 89 (2) , 132-138
- https://doi.org/10.1016/s1081-1206(10)61928-x
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individualsEuropean Respiratory Journal, 2000
- Conformation of the Isolated Cε3 Domain of IgE and Its Complex with the High-Affinity Receptor, FcεRIBiochemistry, 2000
- The pharmacological basis of anti-IgE therapyNature Biotechnology, 2000
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Monoclonal anti-IgE antibody E25 therapy for asthmaResearch in Immunology, 1998
- Consequences of IgE/CD23-mediated antigen presentation in allergyImmunology Today, 1995
- Inhibition of Allergic Reactions with Antibodies to IgEInternational Archives of Allergy and Immunology, 1995
- Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobiumNature, 1991
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensNew England Journal of Medicine, 1989